Warnex Inc.
TSX : WNX

Warnex Inc.

September 06, 2011 07:00 ET

Warnex Launches New Website: www.pca3.ca

LAVAL, QUEBEC--(Marketwire - Sept. 6, 2011) - Warnex Inc. (TSX:WNX) announced today the launch of its new website www.pca3.ca for its PCA3 test for prostate cancer detection, available throughout Canada. Warnex's PCA3 test is a simple, non invasive test performed on a urine sample that informs a patient on their risk of having prostate cancer.

"The Warnex PCA3 test for the detection of prostate cancer is highly specific and more precise than all other available screening tests for prostate cancer," said Mark Busgang, President and CEO of Warnex. "We are pleased to launch this new website, which provides a lot of information for both patients and healthcare providers."

Offered since 2008, Warnex's PCA3 testing service uses advanced PCR technology to detect mRNA from the prostate cancer gene 3 (PCA3). Warnex uses a molecular biology assay to measure the expression of PCA3 mRNA in urine samples. PCA3 is specific to the prostate and is significantly up-regulated (60-100 fold) in prostate cancer. The test quantitatively measures PCA3 mRNA as well as PSA mRNA and determines their ratio. High ratios have been shown to be indicative of prostate cancer. PCA3 screening may help to reduce the number of unnecessary biopsies.

Prostate cancer is the most common cancer in Canadian men. According to Canadian Cancer Society, one in 8 men will develop prostate cancer during his lifetime and one in 27 will die of it. Prostate cancer usually grows slowly and can often be cured or managed successfully.

For more information on Warnex's PCA3 test for prostate cancer, visit www.pca3.ca.

Warnex Medical Laboratories is a leading laboratory for molecular medicine in Canada, offering specialized laboratory testing in various medical specialties, including oncology, endocrinology, haematology, infectious diseases and obstetrics/gynaecology. Warnex Medical Laboratories is accredited by the Standards Council of Canada (ISO 15189) and COLA, a U.S. healthcare accreditation organization, and is certified by the Laboratoire de santé publique du Québec (LSPQ).

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information